Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

10/23/2017 | 04:22am EDT
File photo of a GlaxoSmithKline logo outside one of its buildings in west London

LONDON (Reuters) - GlaxoSmithKline (>> GlaxoSmithKline) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year.

LONDON (Reuters) - GlaxoSmithKline (>> GlaxoSmithKline) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year.

It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

The green light for GSK's shingles shot Shingrix, which has proved significantly better than Merck & Co's (>> Merck and Company) Zostavax in clinical trials, is an important vindication of GSK's product pipeline. The news was announced late on Friday.

GSK's vaccine is considered one of the more pivotal products in its pipeline, with annual sales forecast to reach 1.03 billion pounds ($1.36 billion) by 2023, Thomson Reuters data shows.

"Although largely expected, today’s approval is an important one for GSK -- a new product with a clear best-in-class profile," Berenberg analysts said on Monday. "We expect approval in Europe late this year."

The U.S. Food and Drug Administration (FDA) approval comes a month after it cleared GSK's three-in-one inhaler for chronic lung disease. [nL2N1M00AR]

The third new product GSK expects to launch in the world's biggest drugs market is a dual-drug regimen for HIV, on which the U.S. regulator is scheduled to give a verdict by Dec. 1.

Chief Executive Emma Walmsley, who will present third-quarter financial results on Wednesday, sees the three products as "critical" for GSK's efforts to fill the revenue gap left by falling sales of the ageing lung drug Advair.

The FDA approved Shingrix, which is given in two doses, for adults aged 50 and over. Approval had been expected after an advisory panel to the agency backed the product.

Shingrix is more effective than Zostavax, the only currently available shingles prevention vaccine, which is given as a single dose. GSK said it expects Shingrix to be "available shortly".


The U.S. Centers for Disease Control and Prevention's advisory committee on immunisation practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

The outcome of that meeting may determine just how big the product becomes.

Many analysts expect the committee to recommend routine vaccination of the over-60s, as is currently the case with Zostavax, but an endorsement of use in younger people would represent commercial upside.

Older adults are most at risk of shingles, a painful, often debilitating blistering rash that results from reactivation of the varicella-zoster virus that causes chickenpox and remains latent in those who have had that disease.

Shingrix contains a component from Agenus (>> Agenus Inc), which is entitled to royalties on future sales.

Meanwhile, Britain's National Institute for Health and Care Excellence (NICE) said on Monday that it had approved GSK's gene therapy Strimvelis for treating ADA-SCID -- better known as "bubble boy" disease -- despite its steep price tag of 594,000 euros ($698,000). [nL8N1MV2MT]

Infants with the condition need to be kept in isolation to avoid infections and the cost to the state health service can run to millions of pounds, so a one-off genetic cure can prove cost-effective even at a very high price.

($1 = 0.7581 pounds)

($1 = 0.8508 euros)

(Additional reporting by Bill Berkrot and Deena Beasley; Editing by David Goodman)

By Ben Hirschler

Stocks treated in this article : Agenus Inc, Merck and Company, GlaxoSmithKline

ę Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
AGENUS INC. 2.20% 5.57 Delayed Quote.75.16%
BEST INC. 0.00% 1.06 Delayed Quote.-48.04%
DUAL CO., LTD. 2.59% 4760 End-of-day quote.41.04%
MERCK & CO., INC. -1.22% 75.48 Delayed Quote.-6.59%
STEP CO.,LTD. -1.90% 1756 End-of-day quote.9.96%
All news about AGENUS INC.
08/02AGENUS : to Participate in the BTIG Virtual Biotechnology Conference 2021
07/28AGENUS : MiNK Therapeutics Announces Confidential Submission of Draft Registrati..
07/26AGENUS INC : Change in Directors or Principal Officers (form 8-K)
07/26Agenus Inc. Announces Resignation of Adam F. Krauss, Chief Legal Officer and ..
07/26AGENUS : to Provide Corporate Update and Second Quarter 2021 Financial Report
07/09Agenus Inc. acquired Biomanufacturing Center in Vacaville California, US Stat..
07/07Agenus to Participate in Resistance-Focused Oncology Panel at the William Bla..
07/06AGENUS : Says FDA Accepts Investigational New Drug Application for Cancer Drug C..
07/06Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of..
07/06Agenus Inc. Announces the Closing of its Global Exclusive License with Bristo..
More news
Financials (USD)
Sales 2021 60,0 M - -
Net income 2021 -228 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,41x
Yield 2021 -
Capitalization 1 239 M 1 239 M -
Capi. / Sales 2021 20,7x
Capi. / Sales 2022 12,5x
Nbr of Employees 359
Free-Float 86,6%
Duration : Period :
Agenus Inc. Technical Analysis Chart | AGEN | US00847G7051 | MarketScreener
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,57 $
Average target price 9,00 $
Spread / Average Target 61,6%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.75.16%1 210
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-6.81%28 780